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Abstract
Introduction: Lymphocyte apoptosis has been suggested to play a central role in sepsis pathophysiology, and
studies in animal models demonstrated that blocking this pathway improves outcome. However, no routine
biomarkers of apoptosis are so far available in patients. Thus, the aim of our study was to assess the different
biomarkers of apoptosis putatively usable on a routine basis in septic shock.
Methods: Thirteen septic shock patients (sampled twice between days 1 to 2 and days 3 to 5 after diagnosis of
shock) and 15 sex-matched and age-matched healthy controls were prospectively enrolled. Apoptosis was
measured in lymphocyte subpopulations using flow cytometry (Annexin-V binding, activated caspase-3 and Bcl-2
expressions). Representative pro-apoptotic and anti-apoptotic gene expressions were assessed by quantitative
reverse-transcription PCR. Monocyte HLA-DR expression and lymphocyte subpopulation cell counts were measured
as markers of sepsis-induced immune dysfunctions. To test for statistical significance, the Mann-Whitney U test was
used with correction by the number of tests performed.
Results: Flow cytometric measurements of apoptosis in septic shock patients showed an increased Annexin-V
binding on CD4
+ T cells and an increased active caspase-3 expression on B cells only at days 3 to 5 (sixfold
change and twofold change, respectively). Gene expression analysis showed an increased BCL-XL mRNA and an
upregulation of the pro-apoptotic genes BID and FAS in septic shock patients (10-fold change and fivefold change,
respectively) compared with healthy controls.
Conclusions: The present study highlights the difficulties encountered in monitoring apoptosis on a routine basis
in septic patients, whereas in the same sampling conditions and on the same patients, HLA-DR expression and
lymphocyte subpopulation cell counts showed characteristics described in the literature. However, pro-apoptotic
genes BID and FAS appear to constitute promising apoptosis markers in our hands.
Introduction
Despite advances in supportive care, sepsis remains one
of the most challenging clinical problems worldwide -
constituting the leading cause of death in noncoronary
intensive care units (ICUs) [1].
Sepsis initiates a complex immunologic response that
varies over time with the concomitant occurrence of
both pro-inflammatory and anti-inflammatory mechan-
isms alternatively predominating [1,2]. After a short pro-
inflammatory phase, septic patients enter a stage of pro-
tracted immunosuppression illustrated by reactivation of
dormant viruses (cytomegalovirus or herpes simplex
virus) or infections due to germs normally pathogenic
solely in an immunocompromised host [3]. Importantly,
the intensity and duration of this phase of immunosup-
pression appear to be closely correlated with mortality
and the development of nosocomial infections [1,4].
Although the mechanistic and molecular bases for sepsis-
induced immunosuppression have not yet been fully estab-
lished, alterations of both innate and adaptive immune
responses have been described [1,4]. In particular, an
increased leukocyte apoptosis has been observed in septic
patients [5]. Two major apoptotic pathways are activated:
the extrinsic or death receptor-initiated caspase-8 mediated
pathway, involving the superfamily of TNF receptor mem-
bers; and the intrinsic or mitochondria-initiated caspase-9
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anti-apoptotic members of the BCL-2 family [6].
Interestingly, numerous studies in animal models of sep-
sis showed that blocking programmed cell death improves
outcome after septic challenge [6]. This approach could
thus represent a potential innovative therapeutic strategy
in septic shock. Since no clinical signs of apoptosis have
been described, however, there is thus an urgent need to
develop robust biomarkers available on a routine basis for
the monitoring of this phenomenon. In patients, Weber
and colleagues recently observed an extensive apoptosis of
circulating lymphocytes after severe sepsis (upregulation
of BIM and BID gene expression, and a downregulation of
the anti-apoptotic molecules BCL-2 and BCL-XL) [7].
Parallel to this work, the aim of the current study was
to test the capacity of such well-known markers of
apoptosis (Annexin-V binding, active caspase-3 and
BCL-2 expressions measured by flow cytometry, and the
balance between pro-apoptotic and anti-apoptotic
mRNA expressions measured by quantitative reverse-
transcription (qRT) PCR to detect the activation of this
cell-death pathway in circulating blood of septic shock
patients in the condition of routine laboratory monitor-
ing. Despite increased mRNA expressions of the pro-
apoptotic genes BID and FAS, our results highlight the
difficulties encountered in the monitoring on a routine
basis of apoptosis in septic patients.
Materials and methods
Patients and controls
The present study was conducted in 13 consecutive
patients with septic shock prospectively included accord-
ing to the diagnostic criteria of the American College of
Chest Physicians/Society of Critical Care Medicine [8].
Patients were admitted to the two participating ICUs
(one medical, one surgical) of the Lyon-Sud University
Hospital (Hospices Civils de Lyon, France). Septic shock
was defined by an identifiable site of infection, by hypo-
tension persisting despite fluid resuscitation and requir-
ing vasopressor therapy, and by evidence of a systemic
inflammatory response manifested by at least two of the
following criteria: temperature >38°C or <36°C, heart rate
>90 beats/minute, respiratory rate >20 breaths/minute,
and white blood cell count >12,000/mm
3 or <4,000/mm
3.
The onset of septic shock was defined by the beginning
of vasopressive therapy. The only exclusion criteria were
patients younger than 18 years old and the absence of
circulating leukocytes. Patients were treated according to
the standardized recommendations of our ICUs. Severity
at the onset of shock was assessed by the Simplified
Acute Physiology Score II (range: 0 to 194) [9].
Laboratory analyses were performed on residual ethyle-
nediamine tetraacetic acid-anticoagulated blood after
completing routine follow-up performed in the ICUs, in
accordance with the guidelines for clinical research of
our institute (which, in this case, waived the need for
informed consent). Arterial blood samples were obtained
at days 1 to 2 (D1-2) and days 3 to 5 (D3-5) after the
onset of shock (one sample per period). After blood sam-
pling in the ICUs, tubes were transported at 4°C to the
immunology laboratory within 2 hours in accordance
with our usual routine protocol for monocyte HLA-DR
monitoring [10]. Flow cytometry staining was first per-
formed as described below, and the remaining blood was
then processed to isolate peripheral blood mononuclear
cells (PBMCs) by Ficoll density gradient centrifugation
(within 3 hours). To provide panels of control values for
mRNA quantification and flow cytometry analysis,
15 sex-matched and age-matched healthy individuals
(age 60.6 ± 5.37 years; eight females, seven males) with
no known co-morbidities were also included.
Cell isolation before mRNA analysis
PBMCs were isolated within 3 hours after blood collec-
tion by Ficoll-Paque density gradient centrifugation
(Amersham Biosciences, Björkgatan, Sweden) and
washed with PBS, while the remaining red blood cells
were lysed. Cellular concentration was determined and
cell viability was assessed using the trypan blue exclu-
sion method before the cell pellet was conserved in
RNA Cell Protect (Qiagen, Hilden, Germany) at -20°C
until RNA extraction.
RNA extraction and cDNA synthesis by reverse
transcription
T o t a lR N Aw a se x t r a c t e df r o mP B M C su s i n gR N e a s y
Plus Mini kits (Qiagen). For each RNA extraction, the
residual genomic DNA was digested using the gDNA
Eliminator spin column (Qiagen) and RNA was diluted
in 30 μl elution buffer. RNA quantity was determined
f o re a c hs a m p l eu s i n gaQ u b i t( I n v i t r o g e n ,C a r l s b a d ,
CA, USA) according to the manufacturer’s instructions.
cDNA was then synthesized from 20 ng total RNA
using the WT-Ovation™ System (NuGEN, San Carlos,
CA, USA) powered by Ribo-SPIA™ technology. Briefly,
first-strand cDNA is generated using a unique first-
strand DNA/RNA chimeric primer mix and reverse
transcriptase. mRNA was subsequently fragmented,
allowing the synthesis of a second strand by DNA poly-
merase. Finally, the Ribo-SPIA™ amplification provides
highly efficient amplification of DNA sequences.
Quantitative PCR analysis of apoptotic genes and HLA-DR
Messenger RNA expression was quantified using quantita-
tive PCR. Briefly, PCR reactions were performed in a
LightCycler® 480 instrument using the associated SYBR
Green I Master Mix according to the manufacturer’s
instructions (Roche Molecular Biochemicals, Indianapolis,
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and the cycling conditions were an initial denaturation
step of 95°C for 5 minutes (one cycle), followed by 45
cycles of a touch-down PCR protocol (20 seconds at 95°C,
15 seconds annealing at 68 to 58°C and 15 seconds exten-
sion at 72°C), a melting curve of 95°C for 1 second, 60°C
f o r1 0s e c o n d sa n d9 5 ° Cf o r5m i n u t e s ,a n d ,t of i n i s h ,a
cooling cycle at 40°C for 30 seconds.
The mRNA expression of the housekeeping gene pepti-
dylpropyl isomerase B (PPIB) encoding for cyclophilin B
was investigated using specific cDNA standards and
ready-to-use primer mixes obtained from Search-LC
(Heidelberg, Germany). The efficiency of PPIB mRNA
levels has been previously demonstrated as the reference
for target mRNA quantification in human peripheral
blood [11]. The apoptotic genes (BCL-2, the anti-apoptotic
forms of BCL-XL, BAX, BAK, BIM, BID and FAS) and
HLA-DRA PCR amplicons were obtained with the primer
combinations presented in Table 1. Serial dilutions of the
cDNA were prepared in quadruplicate to generate
standard curves. Relative standard curves, describing the
PCR efficiency of apoptotic genes and PPIB, were created
and used to perform efficiency-corrected quantification
with the LightCycler® software version 1.5. An internal
calibrator was used to compare each cDNA amplification.
The results are expressed as the normalized ratio of BCL-
2 ,B C L - X L ,B A X ,B A K ,B I M ,B I DF A Sa n dH L A - D R A
mRNA relative to PPIB mRNA. The qRT-PCR results
were only included in the analysis if PPIB mRNA values
were comprised within the standard curve - which
accounts for most of the missing values.
Apoptosis measurements by flow cytometry
One hundred microliters of whole blood were incubated
with PE-Cy7-labeled anti-CD3 or anti-CD19 antibodies
and PE-Cy5-labeled anti-CD4 or anti-CD8 antibodies
( B DP h a r m i n g e n ,S a nJ o s e ,C A ,U S A ) ,a n dw e r et h e n
lysed using VersaLyse lysing solution (Beckman-Coulter,
Hialeah, FL, USA).
Apoptosis induction in each specific lymphocyte sub-
population - CD4
+ Tc e l l s( C D 4
+CD3
+), CD8
+ Tc e l l s
(CD8
+CD3
+) and B cells (CD19
+) - was assessed using
Annexin-V binding, intracellular active caspase-3 and
Bcl-2 expression measurements.
Regarding Annexin-V binding experiments, according
to the manufacturer’s protocol, lysed samples were incu-
bated for 15 minutes with PE-labeled Annexin-V
(Annexin-V-PE apoptosis detection kit; BD Pharmingen)
and measured on a flow cytometer within 30 minutes
(FC500; Beckman-Coulter). Results are expressed as per-
centages of respective cell populations positive for
Annexin-V binding. A threshold for positivity was set
up based on nonstained controls.
For active caspase-3 and Bcl-2 intracellular stainings,
following two washes, lysed cells were permeabilized
using Cytofix/Cytoperm reagent (BD Pharmingen) and
were incubated with either PE-labeled anti-active cas-
pase 3 antibodies or PE-labeled anti-Bcl-2 antibodies
(BD Pharmingen). Isotype control antibodies were used
to determine nonspecific binding. After one further
wash, cells were analyzed by flow cytometry. Results are
expressed as the mean fluorescence intensity.
Circulating lymphocyte phenotyping and monocyte
HLA-DR measurements by flow cytometry
Monocyte HLA-DR expression was assessed as described
previously [10]. Representative examples of mHLA-DR
staining by flow cytometry in one patient and one volun-
teer are presented in Figure 1a. The following lymphocyte
subsets were analyzed: total T lymphocytes (CD45
+CD3
+),
CD4
+ T lymphocytes (CD45
+CD4
+CD3
+), and CD8
+
T lymphocytes (CD45
+CD8
+CD3
+). Monoclonal antibo-
dies were used according to the manufacturer’s recom-
mendations: FITC-labeled anti-CD45, PC5-labeled
Table 1 Quantitative reverse-transcription PCR
performance, parameters and primers
Gene
symbol
UniGene Efficiency
a Error
b Primer sequences
c
BCL2 Hs.150749 1.87 0.0059 5’-GCGACGACTTCTCCCGC-3’
5’-GCGATGTTGTCCACCAGG-3’
BCL-XL Hs.516966 1.89 0.0101 5’-
GTAGTGAATGAACTCTTCCG-3’
5’-
GTATCCCAGCCGCCGTTCTC-3’
BAX Hs.
624291
1.75 0.0297 5’-CAAACTGGTGCTCAAGG-3’
5’-CCAACCACCCTGGTCTTGG-
3’
BAK Hs.485139 1.91 0.0175 5’-GCCACCAGCCTGTTTGAG-3’
5’-CTGCCACCCAGCCACCC-3’
BIM Hs.469658 1.95 0.0112 5’-GAGCCACAAGACAGGAGC-
3’
5’-
CCATTGCACTGAGATAGTGG-3’
BID Hs.591054 1.69 0.0184 5’-TGGTGTTTGGCTTCCTCCAA-
3’
5’-
GAATCTGCCTCTATTCTTCCC-3’
FAS Hs.244139 1.93 0.0198 5’-
GGAATCATCAAGGAATGCAC-
3’
5’-
CCAAACAATTAGTGGAATTGG-
3’
HLA-
DRA
Hs.520048 2.04 0.0195 5’-
GCCAACCTGGAAATCATGACA-
3’
5’-AGGGCTGTTCGTGAGCACA-
3’
aAmplification efficiency of standard curve.
bThe standard curve error value.
cTop sequence is forward primer, bottom is reverse primer.
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CD8 (Beckman-coulter). The red cells were lysed on the
automated TQ Prep system (Beckman-Coulter). The abso-
lute count was performed using Flow-count fluorospheres
according to the manufacturer’s recommendations (Beck-
man-Coulter). Results are expressed as numbers of lym-
phocytes per microliter of blood.
Statistical analysis
Values are expressed as medians and interquartile
ranges (Q1 to Q3). Comparisons between healthy con-
trols and septic shock patients (at D1-2 or D3-5) were
made using the nonparametric Mann-Whitney U test,
with P < 0.025 considered statistically significant with
correction by the number of tests performed.
Results
Characteristics of the septic patient cohort
Thirteen patients with septic shock (six women and
seven men) and 15 healthy volunteers (sex-matched and
age-matched) were enrolled in the present study. The
demographic and clinical characteristics of the cohort
are presented in Table 2. None of these patients were
immunocompromised (HIV, cancer, immunosuppressive
treatments). Seven patients received adjunctive corticos-
teroid treatment during their ICU stay.
The total number of leukocytes was increased in sep-
tic patients at D1-2 and D3-5 compared with healthy
volunteers (Mann-Whitney U test; Table 3). In contrast,
the total lymphocyte cell count was significantly dimin-
ished at D1-2 in shock patients compared with normal
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Figure 1 HLA-DR expression in septic shock patients and healthy controls. (a) Cell surface expression of HLA-DR measured by flow cytometry.
A representative CD14 versus side-scattered light (SSC) dotplot and representative HLA-DR linear histograms gated on monocytes in one healthy
volunteer and one septic patient (white histogram = isotype control). (b) Boxplot representations of mHLA-DR measurements by flow cytometry and
quantitative reverse transcription (qRT)-PCR (white boxes, percentage of HLA-DR-expressing monocytes; dashed boxes, normalized ratio of HLA-DRA
mRNA level relative to the housekeeping gene peptidylpropyl isomerase B) measured in whole blood or mononuclear cells from septic shock patients
or healthy controls (n = 10). Values were measured at days 1 to 2 (D1-2, n = 7) and days 3 to 5 (D3-5, n = 10) for septic patients. Normal values: >90%
for flow cytometry and 2 ± 0.3 for mRNA expression. Comparison versus healthy volunteers’ (HV) values (means) performed using the Mann-Whitney U
test with correction for the number of tests performed: *P < 0.025. mHLA-DR values expressed as the number of bound antibodies per cell (AB/c) were
15,985 ± 2,331 at D1-2 and 11,057 ± 2,691 at D3-5 in patients (>15,000 AB/c as indicative of immunocompetence [28]).
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tions, a global decrease in T cells (CD4
+ and CD8
+) was
observed in septic shock patients at D1-2 (Table 3). Our
patient cohort was also characterized by a severely
reduced percentage of HLA-DR-expressing monocytes
measured by flow cytometry and reduced HLA-DRA
mRNA expression measured by qRT-PCR in comparison
with normal values at D1-2 and at D3-5 (Figure 1b).
Annexin-V binding, caspase-3 and Bcl-2 expressions
measured by flow cytometry
We further assessed apoptosis by flow cytometry
(Annexin-V binding, active caspase-3 and BCL-2 expres-
sions). We observed a trend toward an increased
Annexin-V binding on CD4
+ T cells and CD19
+ Bc e l l s
at D1-2 but no change on CD8
+ T cells (Figure 2a).
This increase became significant at D3-5 on CD4
+ T
cells only.
Active caspase-3 expression, the central caspase in the
apoptosis pathway [12], was increased in CD19
+ cells of
septic patients at D3-5 compared with healthy volun-
teers, but no significant changes were observed in CD4
+
and CD8
+ T cells (Figure 2b).
Regarding BCL-2, whatever the time point and T-cell
subpopulation investigated, its protein level measured by
flow cytometry remained similar to that of healthy con-
trols (Figure 2c).
Pro-apoptotic and anti-apoptotic gene mRNA expressions
measured by qRT-PCR
We then analyzed mRNA expressions of the anti-apoptotic
genes BCL-2 and BCL-XL in septic shock patients and
controls (Figure 3). BCL-2 mRNA expression was slightly
decreased in septic shock patients at D1-2 compared with
healthy individuals but returned to normal values at D3-5.
Surprisingly, BCL-XL mRNA levels were significantly
increased in shock patients at both time points compared
with healthy volunteers.
We then measured gene expressions for the BAX-like
proteins (BAX and BAK), the BH3-only proteins (BID
and BIM) and the extrinsic receptor FAS in septic shock
patients and healthy volunteers (Figure 4). Only a trend
toward increased gene expressions of BAX, BAK and
BIM was observed in patients compared with controls
(Figure 4a, b, d). A significantly increased BID mRNA
expression was measured in patients at D1-2 in compar-
ison with healthy volunteers (Figure 4c).
Concerning FAS mRNA expression, we observed a
significant increase in septic patients at D1-2 and D3-5
compared with healthy controls (Figure 4e).
Discussion
Despite studies investigating the role of apoptosis in
septic patients and showing a marked increase in circu-
lating lymphocyte apoptosis associated with a profound
and persistent lymphopenia and with poor outcome
[1,13-15], none have measured programmed-cell death
in routine laboratory conditions. The present study was
thereby designed to test the capacity of well-known
markers of apoptosis to detect this phenomenon on a
routine basis in a cohort of septic shock patients.
Despite the small size of this cohort, clinical character-
istics were similar to those described in the literature for
septic shock patients. Moreover, patients were character-
ized by a decrease in circulating lymphocyte number and
a dramatic downregulation of monocyte HLA-DR expres-
sion at the protein and mRNA levels in accordance with
the literature [10,16].
Regarding apoptosis measurement, flow cytometry
results showed an increased apoptosis at D3-5 in septic
shock patients in CD4
+ T cells (as indicated by
Annexin-V binding) and in B cells (as indicated by
Table 2 Demographic and clinical data for septic shock
patients
Parameter Patients (n = 13)
Age at admission (years) 60 (4)
Gender
Male 7
MacCabe score
01 0
13
Main diagnosis category
Medical 8
Surgical 5
SAPS II score at diagnosis of shock 51 (3)
Adjunctive corticosteroid treatment 7
Delay shock - ICU (days) ≤1
Infection diagnosis
Radiologically diagnosed 1
Surgically diagnosed 0
Microbiologically documented 11
Bacilli Gram-negative 5
Bacilli Gram-positive 6
Fungi 1
Others 1
Type of infection
Community-acquired 10
Hospital-acquired 3
ICU-acquired 0
Site of infection
Pulmonary 6
Abdominal 4
Others 3
Mortality
Survivors 10
Data presented as n or mean (standard error of the mean). ICU, intensive care
unit; SAPS II, Simplified Acute Physiology Score II.
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Page 5 of 10Table 3 Circulating blood leukocyte phenotyping in septic shock patients
Healthy controls Septic shock patients
Days 1 to 2 Days 3 to 5
Leukocytes 5658 (4,954 to 6,146) 14,673 (9,562 to 18,446) 15,390* (10,097 to 25,235)
Lymphocytes 1549 (1,295 to 1,831) 701* (432 to 1,531) 1,110 (634 to 1,482)
T cells 1090 (902 to 1,470) 421* (209 to 547) 529 (335 to 1,031)
CD4
+ T lymphocytes 890 (569 to 1,141) 220* (115 to 354) 479 (218 to 827)
CD8
+ T lymphocytes 320 (228 to 349) 155* (36 to 207) 158 (70 to 304)
Results expressed as the median (interquartile range, Q1 to Q3) number of cells/μl. Blood samples were obtained from 13 septic shock patients at days 1 to 2
and at days 3 to 5 after diagnosis of shock. Circulating leukocyte immunophenotyping was systematically performed by flow cytometry. The following leukocyte
subsets were analyzed: total number of leukocytes, total number of lymphocytes, T cells (CD45
+CD3
+), and CD4
+ (CD45
+CD4
+CD3
+) and CD8
+ (CD45
+CD8
+CD3
+)
T-lymphocyte subpopulations. Comparison versus healthy volunteers values (mean) performed using the Mann-Whitney U test with correction for the number of
tests performed: *P < 0.025.
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Figure 2 Flow cytometric measurement of Annexin-V binding, active caspase-3 and Bcl-2 expressions in lymphocyte subpopulations.
(a) Percentage of cells binding Annexin-V, and the mean fluorescence intensities (MFIs) of (b) active caspase-3 and (c) Bcl-2 expressions were
measured by flow cytometry in CD19
+, CD4
+ and CD8
+ T-lymphocyte subpopulations of healthy volunteers (HV) (open boxes, n = 12) and septic
shock patients (grey boxes) at days 1 to 2 (D1-2, n = 11) and days 3 to 5 (D3-5, n = 10). Data presented as boxplots. Comparison versus healthy
volunteers values (means) performed using the Mann-Whitney U test with correction for the number of tests performed: *P < 0.025.
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Page 6 of 10active caspase 3 staining). These results, however, were
not confirmed by the measurement of a decreased BCL-
2 expression. In parallel, mRNA expression underlined a
surprisingly gradual increase of the BCL-XL gene level
until D3-5 compared with healthy controls, a trend
toward an increased gene expression of BAX, BAK and
BIM, coupled with a massive upregulation of BID and
FAS pro-apoptotic genes. Of note, however, no differ-
ence in apoptosis markers was observed between
patients receiving or not receiving adjunctive corticos-
teroid treatment (data not shown).
Contrary to other studies measuring apoptosis in sep-
tic patients, no clear-cut increase in Annexin-V binding
was observed on B cells and CD8
+ T cells, whereas total
lymphocyte and CD4
+ and CD8
+ lymphocyte numbers
w e r ed e c r e a s e di nt h e s es t u d i e sa sw e l la si no u rs t u d y
[14,15]. Moreover, no significant decrease in BCL-2
gene expression was observed in our hands. One expla-
nation for these discrepancies may be linked with the
difficulties encountered in the monitoring, on a routine
basis, of apoptosis in circulating blood of septic shock
patients. In particular, the delay between blood drawing
in ICU and tube processing in the laboratory (2 hours)
may have lead to sample deterioration, and could thus
explain the slight difference between our results and the
literature. Indeed, such problems have been described in
a recent study investigating the potential of the mea-
surement of Annexin-V binding on lymphocytes as a
biomarker in emergency departments [17].
Regarding mRNA experiments, gene-expression pat-
terns were examined in specific cellular subsets (PBMCs)
in the present study rather than in peripheral whole
blood cells (total mRNA extracted using the PAXgene™
Blood RNA system (PreAnalytix, Hilden, Germany)) as
performed in the study by Weber and colleagues [7]. The
initial goal was to avoid possible interference with neu-
trophils, which are known - contrary to lymphocytes - to
present with decreased apoptosis in critically ill patients
[18,19]. The second goal was to work with only one
blood sample for flow cytometry and qRT-PCR, thereby
reducing the volume of blood collected from patients.
The counterpart, however, ist h a tt h ep r o c e s so fP B M C
purification increases the delay between blood sampling
and mRNA extraction (3 hours), and thus might have
further increased sample deterioration. This is indeed
illustrated in the present study by the high number of
missing values in qRT-PCR experiments due to the low
mRNA extraction yield. Another drawback may be that
PBMCs still constitute a mixture of several cell subpopu-
lations (monocytes and various lymphocyte subsets). As
these subpopulations could have different apoptotic
responses after sepsis, this could limit the value of the
direct comparison between qRT-PCR and flow cytometry
results. If we are to develop a biomarker of apoptosis
usable on a routine basis, however, single cell-population
purification is not possible (time and blood consuming).
PAXgene™ tubes may thus appear the appropriate techni-
que for mRNA study in human blood although they simi-
larly present limitations, including mixed cell populations
and an overabundance of globin gene expression.
With that said, in the current study the expressions of
the pro-apoptotic genes BID and FAS were markedly
upregulated in septic shock patients. This upregulation
suggests that, as opposed to the markers listed before,
BID and FAS might be robust biomarkers of apoptosis
in routine sampling conditions. In Weber and collea-
gues’ article, a similar induction of BID gene expression
was observed in early severe septic patients compared
with critically ill patients [7]. Moreover, in experimental
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Figure 3 Gene expression of anti-apoptotic Bcl-2 family
members measured by quantitative reverse-transcription PCR.
mRNA expressions of anti-apoptotic genes (a) BCL-2 and (b) BCL-XL
were quantified by quantitative reverse-transcription PCR in healthy
controls (open boxes, n = 12) and septic shock patients (grey
boxes) at days 1 to 2 (D1-2, n = 6) and days 3 to 5 (D3-5, n =8 )
after diagnosis of shock. The targeted mRNA levels were normalized
to that of the housekeeping gene peptidylpropyl isomerase B and
are thus expressed as normalized ratio. Data presented as boxplots.
Comparison versus healthy volunteers’ (HV) values (mean)
performed using the Mann-Whitney U test (*P < 0.025, ** P < 0.005).
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Page 7 of 10models of sepsis, BID knockout mice showed nearly
complete protection from sepsis-induced lymphocyte
apoptosis and a marked survival advantage in polymi-
crobial sepsis [20,21].
Regarding FAS, an increased expression was observed
on leukocytes, particularly on neutrophils and mono-
cytes, of humans treated with endotoxin [22]. In septic
patients, PBMCs also exhibited an increase in FAS and
FAS ligand expressions, in correlation with mortality
[23]. Moreover, studies have shown that inhibiting the
FAS-mediated apoptotic pathway (FAS-ligand-deficient
mice or administration of a FAS fusion protein) reduced
mortality in an experimental model of sepsis [20,24,25].
Similarly, FAS inhibition by siRNA given 30 minutes
after cecal ligation and puncture improved survival by
up to 50% and reduced apoptosis and organ damages in
both the liver and the spleen [26].
Conclusions
Lymphocyte depletion, in part due to apoptosis, has been
suggested to play an essential role in the pathophysiology
of sepsis [5,6], and numerous studies suggest that target-
ing apoptosis could thus represent a potential innovative
therapeutic strategy in septic shock [5,6,27]. A step
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Figure 4 Gene expression of pro-apoptotic Bcl-2 family members and death receptor FAS measured by qRT-PCR. mRNA expressions of
pro-apoptotic genes (a) BAX, (b) BAK, (c) BID, (d) BIM and (e) FAS were quantified by quantitative reverse-transcription PCR in healthy
volunteers (HV) (open boxes, n = 11) and septic shock patients (grey boxes) at days 1 to 2 (D1-2, n = 6) and days 3 to 5 (D3-5, n = 8). The
targeted genes mRNA levels were normalized to that of the housekeeping gene peptidylpropyl isomerase B. Data presented as boxplots.
Comparison versus healthy volunteers values (mean) performed using the Mann-Whitney U test (*P < 0.025).
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Page 8 of 10necessary before the use of such therapy in septic
patients, however, is to develop biomarkers of apoptosis
available on a routine basis to identify patients who could
benefit from this treatment before its initiation (that is,
patient stratification). Our results underline the difficul-
ties encountered in the monitoring of apoptosis in septic
shock patients in routine laboratory conditions, whereas
the usual markers of immunoparalysis, such as decreased
monocyte HLA-DR expression, are easily detected (both
at protein and mRNA levels) in the same sampling condi-
tions. This observation suggests it is crucial to develop
specific robust and reliable tools for apoptosis monitor-
ing in septic patients to ensure clinical sample quality in
routine laboratory conditions. Among the markers tested
in the present study, BID and FAS mRNA expressions
appear promising candidates. This deserves to be con-
firmed in a larger and ideally multicentric clinical study.
Key messages
￿ Routine monitoring of apoptosis in septic shock
patients deserves specific protocols.
￿ Septic patients present with decreased monocyte
HLA-DR expression and lymphopenia.
￿ Among parameters measured in this article, FAS
and BID mRNA appear to be promising apoptosis
markers in septic shock.
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